Photo by nci from unsplash
Metformin is a first-line glucose-lowering agent in patients with type 2 diabetes (T2D). Recently in Nature Medicine, Sun et al. (2018) reported that short-term metformin therapy decreases gut Bacteroides fragilis, consequently… Click to show full abstract
Metformin is a first-line glucose-lowering agent in patients with type 2 diabetes (T2D). Recently in Nature Medicine, Sun et al. (2018) reported that short-term metformin therapy decreases gut Bacteroides fragilis, consequently increasing glycoursodexoycholic acid (GUDCA) levels in humans. As an antagonist of FXR, GUDCA may carry therapeutic potential in the treatment of T2D.
Keywords:
feeling metformin;
medicine;
metformin;
gut feeling
Journal Title: Cell metabolism
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cell metabolism
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!